Immuneering Corporation (IMRX)
NASDAQ: IMRX · Real-Time Price · USD
1.180
-0.010 (-0.84%)
May 9, 2025, 10:55 AM - Market open
Immuneering Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
66
Market Cap
42.35M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
IMRX News
- 3 days ago - Immuneering Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewsWire
- 5 weeks ago - Immuneering to Present at the 24th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 6 weeks ago - Immuneering Corporation Announces Grant of Inducement Award - GlobeNewsWire
- 7 weeks ago - Immuneering Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates - GlobeNewsWire
- 7 weeks ago - Immuneering Names Dr. Igor Matushansky as Chief Medical Officer - GlobeNewsWire
- 3 months ago - Immuneering to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewsWire
- 4 months ago - Why Is Immuneering Stock Trading Higher On Tuesday? - Benzinga
- 5 months ago - Immuneering Launches Pancreatic Cancer Advisory Board - GlobeNewsWire